Researchers at Flinders University, in collaboration with international partners, have made significant strides in understanding a rare blood clotting condition associated with certain COVID-19 adenovirus-based vaccines and natural adenovirus infections. This condition, known as vaccine-induced immune thrombocytopenia and thrombosis (VITT), arises when the immune system mistakenly targets a human blood protein, platelet factor 4 (PF4), due to a mix-up with an adenovirus protein.
The study revealed that antibodies created in response to this confusion can activate clotting processes, although such reactions are exceptionally rare. The identification of this mechanism offers a pathway for vaccine developers to modify the adenovirus protein, potentially enhancing vaccine safety while maintaining efficacy against diseases.
Dr. Jing Jing Wang, a lead researcher, emphasized that adjusting or removing the problematic adenovirus protein could prevent the rare adverse reaction associated with VITT. This work is part of a broader inquiry into VITT, which first came to light in 2021 alongside the rollout of adenovirus vector vaccines, including the Oxford-AstraZeneca vaccine.
Previous research has linked VITT to a harmful autoantibody targeting PF4, with studies indicating that the same PF4 antibody could also arise from natural adenovirus infections. Recent findings suggest that antibodies from both vaccine-related and infection-related cases are indistinguishable, implicating the adenovirus itself rather than any specific vaccine component.
The culmination of this research, recently published in the New England Journal of Medicine, showcased advanced techniques in mass spectrometry to elucidate the molecular mimicry responsible for the immune response. Experts in the field have recognized this work as a significant achievement that may lead to the development of safer adenovirus-based vaccines, crucial for global health initiatives, particularly in regions reliant on these vaccines for disease prevention.